drugset / Trial / NCT01557257

Pharmacokinetics Study of ALO-02 and OxyContin

NCT01557257

Phase 1 Completed 13 enrolled Pfizer
RandomizedCrossoverOpen-labelBasic science

Summary

To characterize the single- and multiple-dose pharmacokinetics of oxycodone following the administration of ALO-02 40 Mg Twice Daily, ALO-02 80 Mg Once Daily or Oxycontin 40 Mg Twice Daily in Healthy Volunteers

Timeline

Start
2012-03
Primary completion
2012-05
Completion
2012-05

Drugs

EvaluationDrugModalityDoseRoute
Subject ALO-02 Unknown 40 mg
Subject ALO-02 Unknown 80 mg
Subject Oxycodone Other / unclassified 40 mg
Background Naltrexone Small molecule 50 mg

Indications

No indication recorded.